Literature DB >> 32239325

[Microenvironment in classical Hodgkin lymphoma].

Anja Mottok1.   

Abstract

Classical Hodgkin lymphoma (cHL) is histologically characterized by a quantitatively dominating immune cell infiltrate. Its composition differs depending on the histological subtype and EBV (Epstein-Barr-Virus) status. Current pathogenic concepts postulate that the malignant cells, the so-called Hodgkin and Reed-Sternberg (HRS) cells, act as master recruiters, thereby actively shaping the microenvironment to support their proliferation and outgrowth. This view on the pathogenesis of cHL is further solidified by genetic studies, which have identified important mechanisms by which the HRS cells are enabled to escape immune surveillance. Besides an insufficient antigen presentation mediated by mutations and structural chromosomal changes in key components or regulators of major histocompatibility class I and II molecules, copy number gains of the 9p24.1 genomic locus encompassing JAK2 and the ligands of the programmed cell death protein 1 (PD-1), PD-L1 and PD-L2, play an important role in the pathogenesis of this disease as the engagement of those ligands with their cognate receptor leads to suppression of the immune response. Of importance, the reversibility of this inhibitory receptor-ligand interaction is key to the clinical success that checkpoint inhibitors had and continue to have in cHL patients, especially in the relapse setting. In addition, comprehensive assessment of microenvironment composition, integration with results from genetic studies, and correlation with clinical outcomes have led to the development of prognostic models, which may assist in an improved risk stratification, informed selection of treatment regimens, and therefore better outcomes.

Entities:  

Keywords:  Hodgkin- and Reed-Sternberg cell; Immune escape; PD-1 ligands; Prognostic models; Tumor-associated macrophages

Year:  2020        PMID: 32239325     DOI: 10.1007/s00292-020-00774-z

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  39 in total

1.  High tumour plasma cell infiltration reflects an important microenvironmental component in classic Hodgkin lymphoma linked to presence of B-symptoms.

Authors:  Alex R Gholiha; Peter Hollander; Gustaf Hedstrom; Christer Sundstrom; Daniel Molin; Karin E Smedby; Henrik Hjalgrim; Ingrid Glimelius; Rose-Marie Amini; Gunilla Enblad
Journal:  Br J Haematol       Date:  2018-12-02       Impact factor: 6.998

2.  Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients.

Authors:  Maher K Gandhi; Eleanore Lambley; Jaikumar Duraiswamy; Ujjwal Dua; Corey Smith; Suzanne Elliott; Devinder Gill; Paula Marlton; John Seymour; Rajiv Khanna
Journal:  Blood       Date:  2006-06-06       Impact factor: 22.113

3.  Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell-rich and exhausted T-effector microenvironment.

Authors:  Fathima Zumla Cader; Ron C J Schackmann; Xihao Hu; Kirsty Wienand; Robert Redd; Bjoern Chapuy; Jing Ouyang; Nicole Paul; Evisa Gjini; Mikel Lipschitz; Philippe Armand; David Wu; Jonathan R Fromm; Donna Neuberg; X Shirley Liu; Scott J Rodig; Margaret A Shipp
Journal:  Blood       Date:  2018-06-07       Impact factor: 22.113

4.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Authors:  Michael R Green; Stefano Monti; Scott J Rodig; Przemyslaw Juszczynski; Treeve Currie; Evan O'Donnell; Bjoern Chapuy; Kunihiko Takeyama; Donna Neuberg; Todd R Golub; Jeffery L Kutok; Margaret A Shipp
Journal:  Blood       Date:  2010-07-13       Impact factor: 22.113

Review 5.  Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies.

Authors:  Anja Mottok; Christian Steidl
Journal:  Blood       Date:  2018-03-02       Impact factor: 22.113

6.  Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome.

Authors:  Bruno Chetaille; François Bertucci; Pascal Finetti; Benjamin Esterni; Aspasia Stamatoullas; Jean Michel Picquenot; Marie Christine Copin; Frank Morschhauser; Olivier Casasnovas; Tony Petrella; Thierry Molina; Anne Vekhoff; Pierre Feugier; Reda Bouabdallah; Daniel Birnbaum; Daniel Olive; Luc Xerri
Journal:  Blood       Date:  2008-12-18       Impact factor: 22.113

7.  Expression of CCL5/RANTES by Hodgkin and Reed-Sternberg cells and its possible role in the recruitment of mast cells into lymphomatous tissue.

Authors:  Marie Fischer; Mikael Juremalm; Niclas Olsson; Carin Backlin; Christer Sundström; Kenneth Nilsson; Gunilla Enblad; Gunnar Nilsson
Journal:  Int J Cancer       Date:  2003-11-01       Impact factor: 7.396

8.  Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin's lymphoma cells mediates Up-regulation of CCL20 and the migration of regulatory T cells.

Authors:  Karl R N Baumforth; Anna Birgersdotter; Gary M Reynolds; Wenbin Wei; Georgia Kapatai; Joanne R Flavell; Emma Kalk; Karen Piper; Steve Lee; Lee Machado; Kerry Hadley; Anne Sundblad; Jan Sjoberg; Magnus Bjorkholm; Anna A Porwit; Lee-Fah Yap; Soohwang Teo; Richard G Grundy; Lawrence S Young; Ingemar Ernberg; Ciaran B J Woodman; Paul G Murray
Journal:  Am J Pathol       Date:  2008-05-23       Impact factor: 4.307

9.  Expression of CCL28 by Reed-Sternberg cells defines a major subtype of classical Hodgkin's disease with frequent infiltration of eosinophils and/or plasma cells.

Authors:  Hitoshi Hanamoto; Takashi Nakayama; Hajime Miyazato; Sumio Takegawa; Kunio Hieshima; Yoichi Tatsumi; Akihisa Kanamaru; Osamu Yoshie
Journal:  Am J Pathol       Date:  2004-03       Impact factor: 4.307

10.  HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?

Authors:  Marcel Nijland; Rianne N Veenstra; Lydia Visser; Chuanhui Xu; Kushi Kushekhar; Gustaaf W van Imhoff; Philip M Kluin; Anke van den Berg; Arjan Diepstra
Journal:  Oncoimmunology       Date:  2017-03-03       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.